Zura Bio (NASDAQ:ZURA) Cut to “Strong Sell” at Wall Street Zen

Zura Bio (NASDAQ:ZURA) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued to investors on Sunday.

Several other equities analysts have also weighed in on the stock. William Blair started coverage on shares of Zura Bio in a research report on Wednesday. They issued an “outperform” rating on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zura Bio in a report on Monday, July 6th. Oppenheimer decreased their price target on shares of Zura Bio from $16.00 to $15.00 and set an “outperform” rating on the stock in a research note on Friday, March 20th. Chardan Capital increased their price target on shares of Zura Bio from $10.00 to $11.00 and gave the company a “buy” rating in a report on Monday, March 23rd. Finally, Wedbush restated an “outperform” rating and set a $15.00 price objective on shares of Zura Bio in a research report on Wednesday, July 1st. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $10.75.

Zura Bio Stock Down 7.3%

Shares of ZURA stock traded down $0.40 during trading on Friday, reaching $5.11. 1,254,579 shares of the company’s stock were exchanged, compared to its average volume of 1,557,975. The stock has a market capitalization of $484.84 million, a PE ratio of -4.69 and a beta of -0.03. Zura Bio has a twelve month low of $1.26 and a twelve month high of $7.44. The firm’s fifty day moving average price is $4.45 and its 200-day moving average price is $5.34.

Zura Bio (NASDAQ:ZURA) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.05). As a group, analysts anticipate that Zura Bio will post -0.76 EPS for the current fiscal year.

Hedge Funds Weigh In On Zura Bio

Hedge funds have recently bought and sold shares of the business. Allworth Financial LP bought a new position in shares of Zura Bio in the fourth quarter worth $30,000. Squarepoint Ops LLC lifted its position in Zura Bio by 34.6% during the fourth quarter. Squarepoint Ops LLC now owns 33,801 shares of the company’s stock worth $177,000 after purchasing an additional 8,680 shares during the period. Bank of America Corp DE lifted its position in Zura Bio by 31.9% during the fourth quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock worth $103,000 after purchasing an additional 9,966 shares during the period. Renaissance Technologies LLC grew its stake in Zura Bio by 3.4% during the first quarter. Renaissance Technologies LLC now owns 313,300 shares of the company’s stock worth $1,864,000 after buying an additional 10,200 shares in the last quarter. Finally, Scientech Research LLC bought a new position in Zura Bio in the 3rd quarter valued at about $45,000. 61.14% of the stock is owned by institutional investors.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.